551. Local Nogo-66 administration reduces neuropathic pain after sciatic nerve transection in rat.
- Author
-
Li L, Qin H, Shi W, and Gao G
- Subjects
- Animals, Disease Models, Animal, Male, Neuroma drug therapy, Neuroma pathology, Nogo Proteins, Pain Measurement methods, Rats, Rats, Sprague-Dawley, Reaction Time drug effects, Time Factors, Analgesics administration & dosage, Myelin Proteins administration & dosage, Sciatica drug therapy
- Abstract
Neuropathic pain after periphery nerve injury is frequently accompanied by the regeneration of the injured nerve fibers. We tested in this study whether local administration of Nogo-66, a well-studied axon growth inhibiting peptide in the central nerve system, could reduce the pain related behavior after sciatic nerve transection in rat. Nogo-66 peptide was purified as a GST fusion protein. Its inhibitory function was testified by neurite outgrowth assay of primary cultured neurons, and then it was given directly at the lesion site by a minipump for 2 weeks. Mechanical nociceptive withdrawal responses and heat hyperalgesia responses were assessed during a 4-week period, and autotomy was evaluated during a 6-week period. The results showed that the mechanical allodynia and heat hyperalgesia scores of the rats treated with GST-Nogo-66 were significantly higher than the controls between 7 and 14 days after sciatic nerve transection. The autotomy scores in the GST-Nogo-66 group were significantly lower than the controls from 28 days after surgery. Taken together, the results of our present study suggest that Nogo-66 may be utilized to decrease the neuropathic pain after periphery nerve injury.
- Published
- 2007
- Full Text
- View/download PDF